Jasper Therapeutics (JSPR) PT Lowered to $48 at RBC Capital; Stock Pressured Following BEACON's Initial Data
Tweet Send to a Friend
RBC Capital analyst Gregory Renza lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $48.00 (from $68.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
